Xilio Therapeutics, Inc. (XLO)
NCM · Healthcare · Biotechnology
$8.93
+0.00%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$58.8M
Shares Outstanding
6.6M
P/S (TTM)
0.9x
Exchange
NCM
Currency
USD
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 19.1M | 13.7M | 12.6M | 18.7M |
| Operating Income | (1.9M) | (11.8M) | (14.1M) | (3.5M) |
| Net Income | (16.3M) | 10.4M | (9.5M) | (6.4M) |
| Diluted EPS | $-1.54 | $0.81 | $-0.58 | $-0.33 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 6.3M | 43.8M |
| Operating Income | (89.1M) | (79.1M) | (59.6M) | (42.0M) |
| Net Income | (88.2M) | (76.4M) | (58.2M) | (35.0M) |
| Diluted EPS | $-45.08 | $-38.92 | $-15.26 | $-4.19 |